[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100524784":3},{"organization":4,"armGroups":7,"interventions":18,"overallOfficials":10,"centralContacts":27,"locations":33,"responsibleParty":57,"collaborators":10,"id":59,"slug":10,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":10,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":10,"maxAge":10,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":76,"overallStatus":36,"whyStopped":10,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"Jazz Pharmaceuticals","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Retrospective Pregnancy",null,"Participants who were exposed to at least one dose of Epidiolex\u002FEpidyolex in routine practice during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy and is no longer pregnant at the time of study enrollment.",[13],"Drug: Epidiolex",{"label":15,"type":10,"description":16,"interventionNames":17},"Prospective Pregnancy","Participants who were exposed to at least one dose of Epidiolex\u002FEpidyolex in routine practice during the 13 days prior to last menstrual period (LMP) or at any time during their pregnancy and is pregnant at the time of study enrollment.",[13],[19],{"type":20,"name":21,"description":22,"armGroupLabels":23,"otherNames":24},"DRUG","Epidiolex","Oral solution",[15,9],[25,26],"Epidyolex","Cannabidiol",[28],{"name":29,"role":30,"phone":31,"phoneExt":10,"email":32},"Clinical Trial Disclosure & Transparency","CONTACT","215-832-3750","ClinicalTrialDisclosure@JazzPharma.com",[34,47],{"facility":35,"status":36,"city":37,"state":38,"zip":39,"country":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":10},"United Biosource LLC","RECRUITING","Morgantown","West Virginia","26508","United States",{"type":42,"coordinates":43},"Point",[44,45],-79.9559,39.62953,{"lat":45,"lon":44},{"facility":48,"status":36,"city":49,"state":10,"zip":50,"country":51,"cosmosGeoPoint":52,"geoPoint":56,"contacts":10},"Vivantes Humboldt-Klinikum Klinik für Neurologie","Berlin","13509","Germany",{"type":42,"coordinates":53},[54,55],13.41053,52.52437,{"lat":55,"lon":54},{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100524784",false,"NCT06113237","Pregnancy Surveillance Program of Patients Exposed to Epidiolex\u002FEpidyolex During Pregnancy","Observational Pregnancy Surveillance Program of Patients Exposed to Epidiolex\u002FEpidyolex During Pregnancy to Assess the Risk of Pregnancy and Maternal Complications and Other Events of Interest on the Developing Fetus, Neonate, and Infant","Inclusion Criteria:\n\n1. Patients with exposure to at least 1 dose of Epidiolex\u002FEpidyolex during the 13 days prior to their LMP or at any time during pregnancy.\n2. Verbal or written informed consent to participate\n\nExclusion criteria:\n\n1\\) Patients exposed to a non-regulatory approved product containing Cannabidiol (CBD) during pregnancy who do not also have exposure to Epidiolex during the 13 days prior to their LMP or during the pregnancy.","FEMALE",{"count":67,"type":68},50,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to evaluate pregnancy-related health outcomes in participants who are exposed to Epidiolex\u002FEpidyolex during pregnancy and their infant up to 12 months of life.",[72,73,74,75],"Maternal Complications","Pregnancy Complication","Birth Outcomes, Adverse","Pregnancy",[21,25],"2026-06-26",{"date":79,"type":80},"2026-06-29","ACTUAL",{"date":82,"type":80},"2025-08-05",{"date":84,"type":68},"2033-08-31",{"name":5,"class":6},2]